Trial
NCT01198067
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Waldenstrom Macroglobulinemia
Intervention
Pomalidomide
Why stopped
\<75% participant accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-04